About Evozyne
Evozyne is a company based in Chicago (United States) founded in 2020 by Andrew Ferguson and Rama Ranganathan. Evozyne has raised $144.37 million across 4 funding rounds from investors including Fidelity Investments, Paragon Biosciences and Orbimed. Evozyne offers products and services including AI Protein Design Platform and Partnership Pipeline. Evozyne operates in a competitive market with competitors including Nimbus Therapeutics, Cradle, EvolutionaryScale, Profluent Bio and Frontier Medicines, among others.
- Headquarter Chicago, United States
- Founders Andrew Ferguson, Rama Ranganathan
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Evozyne, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$144.37 M (USD)
in 4 rounds
-
Latest Funding Round
$81 M (USD), Series B
Sep 14, 2023
-
Investors
Fidelity Investments
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Evozyne
Evozyne offers a comprehensive portfolio of products and services, including AI Protein Design Platform and Partnership Pipeline.
Platform that designs novel proteins using Generative AI for medical applications
System for advancing protein therapeutics through investor and advisor partnerships
People of Evozyne
Unlock access to complete
Unlock access to complete
Scientific Team
6 people
Leadership Team
1 people
Chair Team
1 people
Co Team
1 people
Unlock access to complete
Funding Insights of Evozyne
Evozyne has successfully raised a total of $144.37M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $81 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Evozyne
Evozyne has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Paragon Biosciences and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Private equity firm
|
Locked | Locked | Locked | |
|
Venture capital arm of Nvidia
|
Locked | Locked | Locked |
Investor details for Evozyne
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Evozyne
Investment portfolio details for Evozyne
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Evozyne
Detailed financials for Evozyne
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Evozyne Comparisons
Peer comparison for Evozyne
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Evozyne
Evozyne operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nimbus Therapeutics, Cradle, EvolutionaryScale, Profluent Bio and Frontier Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Chemoproteomics solutions are provided for protein design and development.
|
|
| Locked | Locked | Locked |
Provider of an AI models for protein design
|
|
| Locked | Locked | Locked |
An AI-based protein design platform is provided for drug discovery.
|
|
| Locked | Locked | Locked |
Bioinformatics platform is developed for drug discovery and chemoproteomics.
|
Detailed competitors of Evozyne
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Evozyne
Complete news archive for Evozyne
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Evozyne
Evozyne was founded in 2020.
Evozyne is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Evozyne is a funded company, having raised a total of $144.37M across 4 funding rounds to date.
Evozyne has developed novel proteins using protein engineering technology. The company uses machine learning, statistical techniques with high throughput gene synthesis and screening technology to build predictive models of sequence-function relationships for a family of proteins for synthesis, and characterizing of the proteins.
Evozyne's top competitors include Nimbus Therapeutics, Cradle and Profluent Bio.
Evozyne offers AI Protein Design Platform and Partnership Pipeline.
Evozyne has 5 investors. Key investors include Fidelity Investments, Paragon Biosciences, Orbimed, Valor Equity Partners, and NVentures.